ACADIA Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ACAD and other ETFs, options, and stocks.

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

CEO

Catherine Owen Adams

CEOCatherine Owen Adams

Employees

654

Employees654

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1993

Founded1993

Employees

654

Employees654

ACAD Key Statistics

Market cap

3.53B

Market cap3.53B

Price-Earnings ratio

15.70

Price-Earnings ratio15.70

Dividend yield

—

Dividend yield—

Average volume

2.34M

Average volume2.34M

High today

$21.34

High today$21.34

Low today

$20.54

Low today$20.54

Open price

$21.05

Open price$21.05

Volume

1.64M

Volume1.64M

52 Week high

$26.65

52 Week high$26.65

52 Week low

$13.40

52 Week low$13.40

ACAD News

TipRanks 21h

ACADIA Pharmaceuticals: Hold Rating Amid Pipeline Shifts and Product Focus

ACADIA Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Sean Laaman from Morgan Stanley maintained a Ho...

Simply Wall St 6d

Do ACADIA Pharmaceuticals’ Pipeline Updates Reveal a Shifting Focus Beyond NUPLAZID?

Acadia Pharmaceuticals recently presented a late-breaker oral platform presentation and two poster sessions at the International Congress of Parkinson's Disease...

Analyst ratings

63%

of 19 ratings

Buy

63.2%

Hold

31.6%

Sell

5.3%

People also own

Based on the portfolios of people who own ACAD. This list is generated using Robinhood data, and it’s not a recommendation.